News
Talecris launches public offering of 45 million shares
RRT News
Biotechnology and biotherapeutic company Talecris Biotherapeutics said Tuesday it has launched its initial public offering, or IPO, of 44,736,842 shares of its common stock at a par value of $0.01 per share.
Talecris is the maker of Prolastin, an augmentation therapy for Alpha-1 Antitrypsin Deficiency, and other plasma-based therapies.
The North Carolina-based company expects to use the net proceeds from the offering to pay down debt.
Talecris stated that, out of the total shares that are being offered, 28,947,368 are being offered by Talecris and 15,789,474 are being offered by Talecris Holdings, LLC, the selling shareholder.
The IPO price is estimated to be in the range of $18.00 to $20.00 per share.
The company said it has applied to have the shares of common stock approved for quotation on The Nasdaq Global Market under the ticker symbol “TLCR.”
In addition to this, Talecris also said the underwriters have the option to buy up to an additional 6,710,526 shares of common stock from the selling shareholder, on the same terms and conditions.
The company noted that it will not get any of the proceeds from the offering of the common stock by the selling shareholder.
Talecris Holdings is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures.
